Overall, we have shown for the first time that BCP mediates an antiangiogenic effect via changes in the tumor cell microenvironment through CB2 receptor-driven VEGF inhibition, which may represent an attractive option for the treatment of tumors. The gene discussed is VEGFA; the disease is neoplasm.